• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 3. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 4. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 5. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200

Research Briefing on BORONIC ACID, [4-(4,4-DIMETHYLCYCLOHEXYL)PHENYL]- (CAS: 865360-61-8) in Chemical Biology and Pharmaceutical Applications

BORONIC ACID, [4-(4,4-DIMETHYLCYCLOHEXYL)PHENYL]- (CAS: 865360-61-8) is a boronic acid derivative that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. Boronic acids are known for their unique ability to form reversible covalent bonds with diols and other nucleophiles, making them valuable tools in drug discovery, proteomics, and materials science. This compound, with its specific cyclohexylphenyl substitution pattern, exhibits distinct physicochemical properties that may enhance its utility in targeted therapeutic and diagnostic applications.

Recent studies have explored the role of BORONIC ACID, [4-(4,4-DIMETHYLCYCLOHEXYL)PHENYL]- in the development of novel proteasome inhibitors and as a key intermediate in the synthesis of biologically active molecules. The compound's structural features, including the hydrophobic cyclohexyl group and the reactive boronic acid moiety, contribute to its ability to interact with specific enzyme active sites, particularly those involved in inflammatory and oncogenic pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a building block for covalent inhibitors targeting the 20S proteasome, showing promising results in in vitro models of multiple myeloma.

In the context of drug delivery systems, researchers have investigated the potential of this boronic acid derivative to serve as a pH-responsive linker for antibody-drug conjugates (ADCs). The compound's ability to form stable boronate esters with sugar moieties under physiological conditions, while undergoing hydrolysis in acidic environments (such as tumor microenvironments or lysosomes), makes it an attractive candidate for targeted drug release strategies. A recent patent application (WO2023056421) describes its incorporation into next-generation ADC platforms with improved pharmacokinetic profiles and reduced off-target effects.

The synthetic accessibility of BORONIC ACID, [4-(4,4-DIMETHYLCYCLOHEXYL)PHENYL]- has also been a focus of recent methodological developments. A 2024 publication in Organic Letters presented a novel palladium-catalyzed borylation protocol that significantly improves the yield and purity of this compound, addressing previous challenges in large-scale production. This advancement is particularly relevant for pharmaceutical applications where consistent quality and scalability are critical factors in preclinical and clinical development.

Emerging research suggests potential applications of this compound in the field of chemical biology probes. Its ability to selectively label glycoproteins through boronic acid-diol interactions has been exploited in new imaging techniques for tracking post-translational modifications. Furthermore, computational studies have predicted favorable binding interactions between this boronic acid derivative and several carbohydrate-binding proteins, opening possibilities for its use in glycomics research and the development of carbohydrate-based therapeutics.

As research continues to elucidate the full potential of BORONIC ACID, [4-(4,4-DIMETHYLCYCLOHEXYL)PHENYL]-, several challenges remain to be addressed. These include optimizing its selectivity profile for specific biological targets, improving its metabolic stability, and developing formulations that enhance its bioavailability. However, the compound's versatility and the growing understanding of boronic acid chemistry in biological systems position it as a promising candidate for future therapeutic and diagnostic innovations in chemical biology and precision medicine.

• 374538-04-2(4-Cyclohexylphenylboronic acid)
• 136321-96-5((4-(4-Pentylcyclohexyl)phenyl)boronic acid)
• 315220-11-2(4-(4-Butylcyclohexyl)phenylboronicacid)
• 156837-90-0((4-(4-Propylcyclohexyl)phenyl)boronic Acid)
• 1264296-84-5(4-(1-methylcyclopropyl)phenylboronic acid)
• 850568-56-8((4-sec-Butylphenyl)boronic Acid)
• 945837-57-0(4-Cyclopentylphenylboronic acid)
• 146862-02-4(4-(Trans-4-N-propylcyclohexyl)phenylboronic Acid)
• 143651-26-7((4-(trans-4-Pentylcyclohexyl)phenyl)boronic Acid)
• 164220-57-9(trans-[4-(4-ethylcyclohexyl)phenyl]boronic acid)